Swedish Orphan Biovitrum (OTCMKTS:BIOVF - Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.24 earnings per share for the quarter, topping analysts' consensus estimates of $0.18 by $0.06, Zacks reports. Swedish Orphan Biovitrum had a return on equity of 11.93% and a net margin of 16.05%. The company had revenue of $649.61 million for the quarter, compared to analyst estimates of $644.68 million.
Swedish Orphan Biovitrum Stock Performance
Shares of BIOVF remained flat at $29.79 during mid-day trading on Friday. The company has a market cap of $10.61 billion, a PE ratio of 25.03 and a beta of 0.42. The company has a current ratio of 1.04, a quick ratio of 0.71 and a debt-to-equity ratio of 0.31. Swedish Orphan Biovitrum has a 1 year low of $24.08 and a 1 year high of $32.25. The business's 50-day moving average price is $30.05 and its two-hundred day moving average price is $29.36.
Swedish Orphan Biovitrum Company Profile
(
Get Free Report)
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.
Featured Stories
Before you consider Swedish Orphan Biovitrum, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Swedish Orphan Biovitrum wasn't on the list.
While Swedish Orphan Biovitrum currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access